This is a Phase II randomized, double-masked study comparing the safety and efficacy of ATG003 (mecamylamine HCl) 1.0% and 0.3% ophthalmic solutions to placebo in patients with neovascular ("wet") age-related macular degeneration (NV-AMD).
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Enrollment
343
Proportion of Subjects Losing Fewer Than 15 ETDRS Letters of Visual Acuity at 48 Weeks Compared to Baseline.
Time frame: Baseline to Week 48
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Hospital de Olhos de Araraquara
Araraquara, Brazil
Centro Brasileiro de Ciências Visuais
Belo Horizonte, Brazil
Instituto da Visão
Belo Horizonte, Brazil
Centro Brasileiro de Cirurgia dos Olhos
Goiânia, Brazil
Hospital de Clinicas de Porto Alegre
Porto Alegre, Brazil
Hospital Universitário Clementino Fraga Filho
Rio de Janeiro, Brazil
Clínica de Olhos Dr. Suel Abujamra
São Paulo, Brazil
Hospital das Clínicas Faculdade de Medicina da Universidade de São Paulo
São Paulo, Brazil
Hospital de Olhos de São Paulo
São Paulo, Brazil
Hospital São Paulo - Setor de Pesquisa Clínica
São Paulo, Brazil
...and 32 more locations